Key Takeaways
- Recovery underway, led by crop protection: Revenue and profitability improved both QoQ and YoY, with the crop protection segment delivering 68% YoY revenue growth and a seven-fold EBITDA jump as global channel destocking ended.
- Pricing remains the missing piece: Despite volume and mix-driven growth, selling prices are still flattish and low, with Chinese overcapacity continuing to suppress the market. Management hopes for gradual improvement, not a spike.
- Anti-dumping tailwinds are structural, not immediate: India imposed ADD on Chinese TiO2 and the US on 2,4-D, where Meghmani got the lowest duty. Benefits will materialize only once pre-duty Chinese inventory clears, likely from Q3 FY26.
- Margins normalized but fragile: A 17% margin this quarter is described as a "normal average" for the industry; management won't promise it holds, citing persistent pricing pressure and deliberate inventory build-up.
- What to watch next quarter: Whether the TiO2 utilization ramp actually begins as paint customers open their doors, any sign of pricing lift in crop protection, and the pace of new product registration conversions in Brazil.
Crop Protection: The Recovery Engine
- Demand restart, not price restart: The 68% YoY revenue jump and 24% sequential improvement came from volume recovery and a deliberate shift to higher-value new-generation products, not from better pricing. Volume grew only 6%, so mix drove the revenue outperformance.
- Channel destocking done: Global channel inventory has reached reasonable levels after two years of destocking, and new demand has started picking up. No one in the chain holds high-priced inventory anymore, which removes a structural overhang.
- China still the price-setter: Chinese producers continue selling at very low prices and are themselves "bleeding heavily." Overcapacity persists, and while Xi Jinping has urged companies to stop dropping prices, no concrete supply-side action has materialized yet.
- Strategy pivot to new products: Management shifted from old generic products to new molecules developed over the last 5–6 years (Cyfluthrin, Beta Cyfluthrin, Ethiprol, Pymetrozine, Spiromesifen, Flumendamide, Flonicamid), improving the product mix and insulating growth from pure commodity price cycles.
- MPP plant not yet material: The multipurpose plant contributed ~₹250 crores in the full previous year but was not a material contributor this quarter. Utilization is improving and management expects significant contribution going forward.
- First 9(3) combo registration in India: Received the first 9(3) combo patented registration for the Indian market: Flonicamid plus Fipronil, a differentiated formulation that supports the mix-improvement strategy.
Patel: "So far, there has not been much improvement in the pricing, but we hope that it should start happening. But it won't be like what we have seen in the year of '20, '21, '22 that was unrealistic price increase."
Titanium Dioxide: The Anti-Dumping Catalyst
- The duty changes the access equation: On 10th May 2025, India imposed anti-dumping duty of $460 to $681 per metric ton on Chinese TiO2. Previously, large Indian paint companies (1,500+ in the market) did not prioritize domestic manufacturers because cheap Chinese supply was freely available. Post-ADD, those customers have "started opening the door" and samples have begun going to top players.
- Utilization was abysmal, now set to improve: Capacity utilization was "quite low" due to Chinese dumping pressure. With the ADD in place, demand has started improving and utilization will follow, though management will give clearer numbers only in Q3.
- The Q3 timeline is structural, not cautious: The benefit won't flow immediately because Chinese producers built up channel inventory in India before the duty took effect. That inventory must liquidate first, so the actual price and volume impact is expected from Q3 FY26 onwards.
- China's pain is the upside catalyst: Chinese TiO2 companies are "bleeding heavily" across segments. Management expects plant shutdowns or consolidation eventually, which would improve global pricing. Xi Jinping's intervention to curb price wars is an early signal, but no action yet.
- Ramp-up is phased: The first target is to stabilize the current phase with better realization and run the plant at better capacity. Parallel planning for the next level of ramp-up exists but details were not disclosed.
Patel: "What we feel that because of this slowly, gradually Chinese companies would also like to improve the pricing. There may be shut down in certain plants or consolidation, something will happen. But ultimately, in the long run, there will be improvement in the pricing. So this is tough time, but we have to keep on fighting."
US Tariffs: A Relative Advantage
- 25% tariff was a surprise: Management's internal assumption was 10% to 15%; the 25% reciprocal tariff plus an unknown penalty amount came in higher than expected. The team has started analyzing the impact.
- The China comparison is the silver lining: China faces total US tariffs of approximately 55% (25% + 20% + 10%) versus India's 25% reciprocal tariff. Management's early read is that India remains "better off than China," which could create a relative competitive shift in the US market.
- 2,4-D anti-dumping win: The US also imposed anti-dumping duty on 2,4-D on both India and China. Meghmani received the lowest duty among all companies, while China's duty is ~130%+. This is a structural competitive moat in that product.
Patel: "It came as a surprise. We as an Indian company, we were clear that there will be some tariffs, no doubt about it. But it would be probably in the range of 10% to 15%. That was our internal assumption. But the 25% has come as a surprise, but our team has started doing the analysis."
Pigments: Steady, Not a Growth Story
- Low utilization, thin margins: Capacity utilization at 46% with EBITDA margin around 5.3%. Management runs this segment at an optimized level and does not expect significant growth, maybe ₹50–60 crores of variation.
- Focus is on realization, not volume: The strategy is to optimize between export and domestic markets for better price realization wherever possible. No major capex or expansion is planned here.
New Growth Vectors: Brazil, Nano Urea, Kilburn
- Brazil subsidiary is the next structural bet: The company started focusing on Brazil in 2017, has secured a few registrations with many more in the pipeline, and plans to open a 100% Brazilian subsidiary. Over the next 3–4 years, a few registrations will come every year. When volume is needed, it will come from US and Latin American markets.
- Nano Urea going global: Received registrations in 7 international markets for Meghmani Nano Urea. Double-digit growth expected this year, with the next 2–3 years driving major growth in this segment.
- Kilburn as the domestic story: Management is "very optimistic" on crop nutrition (Kilburn), describing it as the domestic growth story with tremendous growth expected. Details on further product additions were deferred until after first-phase stabilization.
- Registration pipeline is the moat-in-progress: New product registrations are ongoing across the US, Argentina, Africa, and Asian markets, including both technical and formulation registrations and new combination formulations.
Financial Health: Debt, Margins, and One-Offs
- Debt reduction underway: Repaid approximately ₹38 crores of debt during the quarter, with a stated aim to continue reducing debt levels. No significant capex is planned for the current financial year.
- Inventory build-up was deliberate: A sharp increase in inventory change led to higher COGS. Management chose to build inventory because raw material was at rock-bottom levels, demand is picking up, and higher inventory is needed to run plants at better capacity. This will continue.
- Forex hit on finance costs: Finance costs rose due to forex volatility as the euro moved from 92 to 100 in the quarter. The company borrows in INR while holding long-term loans in euro and dollar, creating a net forex impact of ~₹7 crores after offsetting currency gains in other income. Management emphasized it does not speculate on forex.
- Tax rate normalizing: The higher tax rate this quarter reflects MCNL turning profitable for the first time, with no deferred tax impact created as management sees profitability going forward in all segments. The expected tax rate going forward is around 25%.
- Logistics costs stabilizing: Logistics costs were volatile last year due to war conditions but have now started reducing and reached a reasonable level. If nothing volatile happens globally, they should remain stable.
Patel: "It is difficult to promise that we'll maintain this kind of profitability. But yes, there will always be the try to have the higher profitability."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Crop protection growth | Double-digit CAGR | Next 3 years |
| TiO2 price/volume impact from ADD | Material benefit expected after pre-duty Chinese inventory clears | From Q3 FY26 |
| TiO2 clarity | Management will provide clearer picture on segment numbers | Q3 FY26 |
| Debt reduction | Continue reducing debt levels | Coming quarters |
| Nano Urea growth | Double-digit growth this year; major growth thereafter | This year and next 2–3 years |
| Brazil registrations | A few registrations every year | Next 3–4 years |
| Crop protection pricing | Some improvement expected | After 1–2 quarters |
| Tax rate | Around 25% | Going forward |
| New product additions (crop protection) | 2–3 new products | This financial year |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue (standalone) | ₹593 cr, +44% YoY |
| Revenue (consolidated) | ₹614 cr, +48% YoY |
| EBITDA (standalone) | ₹81 cr, nearly 6x from ₹14 cr in Q1 FY25 |
| EBITDA (consolidated) | ₹67 cr, 11x from ₹5.9 cr in Q1 FY25 |
| PAT (standalone) | ₹40 cr, against a loss of ₹6.3 cr in Q1 FY25 |
| PAT (consolidated) | ₹12.7 cr, against a loss of ₹16.8 cr in Q1 FY25 |
| Crop Protection revenue | ₹458 cr, +68% YoY; 77% of total revenue |
| Crop Protection EBITDA margin | 17.3% |
| Crop Protection capacity utilization | 78%, production up 6% YoY to 10,600 MT |
| Pigment revenue | ₹135 cr, 23% of total revenue |
| Pigment EBITDA margin | 5.3% |
| Pigment capacity utilization | 46%, production up 1% YoY to 3,700 MT |
| Total debt (standalone) | ₹562 cr, ₹380 cr short-term and ₹182 cr long-term as of 30 Jun 2025 |
| Total debt (consolidated) | ₹809 cr, ₹399 cr short-term and ₹409 cr long-term as of 30 Jun 2025 |
| Debt repaid during quarter | ₹38 cr |
| Nano Urea revenue (FY25) | ₹40 cr, double-digit growth expected in FY26 |
| MPP revenue (FY25) | ₹250 cr, significant improvement expected in FY26 |
| Brazil registrations | 6 on hand, more than 30–35 in pipeline |
| US reciprocal tariff on India | 25% plus penalty, imposed Jul 2025 |
| Anti-dumping duty on Chinese TiO₂ | $460 to $681 per MT, imposed 10 May 2025 |
| Net forex impact | ₹7 cr loss, MTM loss of ₹15 cr offset by ₹8 cr currency gain |
| Expected tax rate | ~25% going forward |